Digest Network Come funziona
Network
/
Società
Ne
Non verificato

Neurotech Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOtticaSalute

6 comunicati stampa

Guarda tutti i comunicati
29/09/2025
Biotecnologia
Salute
Farmaceutica
Ottica
Industria
Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025
Fonte
Neurotech Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/09/2025
Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
Fonte
Neurotech Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/08/2025
Salute
Igiene alimentare
Attrezzature medico-sanitarie
Farmaceutica
Ottica
Biotecnologia
Industria
First FDA-Approved Treatment for MacTel Performed
Fonte
Neurotech Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
21/04/2025
Neurotech Appoints Beth Marsh as Chief Commercial Officer
Fonte
Neurotech Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/03/2025
Industria
Igiene alimentare
Salute
Farmaceutica
Ottica
Biotecnologia
Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)
Fonte
Neurotech Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/11/2024
Industria
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
Fonte
Neurotech Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0